natgillin/translations-raw huggingface dataset:
The receiver can be installed in a variety of locations on the boat, though preferably not in the engine room, to avoid thermal or mechanical damage. 
Prijemnik se može postaviti na raznim mjestima na plovilu, iako po mogućnosti ne u prostoru za motore, kako bi se izbjeglo toplinsko ili mehaničko oštećenje.
acute lymphocytic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, or multiple myeloma; or 
akutna limfocitna leukemija, kronična mijelocitna leukemija, kronična limfocitna leukemija, ili multipli mijelom; ili
The amounts thereof are variable, but from at least 0.1% (w/v) and up to 35% (w/v) or more of the polymeric moiety should be considered, with an amount of about 20% (w/v) being preferred. 
Antiparazitna smjesa za polijevanje koja sadrži učinkovitu količinu salicilanilidnog anti-parazitnog spoja, naznačena prisutnošću transdermalnog sustava primjene koji sadrži barem 20% (v/v) jednog ili više od C;-Cg monohidro alkilnih alkohola 1 do 35% (t/v) polimernog dijela.
The use of a gas diffusion electrode according to claim 7, wherein said fuel cell is a biological fuel cell. 
Primjena plinske difuzijske elektrode u skladu s zahtjevom 7, naznačena time da je navedena goriva ćelija biološka goriva ćelija.
The liquefied gas treatment system according to claim 1, wherein the third stream liquefied in the heat exchanger is decompressed by decompressing means. The liquefied gas treatment system according to claim 2, wherein the third stream decompressed to a gas-liquid mixed state is returned to the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se tekuću komponentu BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje (22), vraća u spremnik za teret (1;11)
In further embodiments, the pharmaceutical composition of the present invention comprising a PRG4 protein in combination with one or more ophthalmically acceptable agents discussed above further comprises a therapeutically effective concentration of hyaluronic acid or sodium hyaluronate in the range of 10-100,000 ug/mL, preferably 500-5,000 ug/mL. 
Farmaceutski oblik za uporabu prema bilo kojem od zahtjeva 1 do 3, dalje sadrži terapijski učinkovitu koncentraciju natrijevog hijaluronata ili hijaluronske kiseline. Farmaceutski oblik za uporabu prema zahtjevu 5, gdje farmaceutski oblik sadrži natrijev hijaluronat ili hijaluronsku kiselinu u terapijski učinkovitoj koncentraciji od 10-100,000 ug/mL.
After removal of solvent in vacuo purification of the resulting solid on silica gel (15% ethyl acetate/ dichloromethane) gave a white solid. 
Nakon uklanjanja otapala uz podtlak, pročišćavanje nastale krutine na silikagelu (15% etil-acetat/ diklormetan) dalo je bijelu krutinu.
wherein the flexible tip member is partially disposed within the sleeve, in use, such that the distal end of the flexible tip member extends distally through the opening in the distal end of the sleeve, and the proximal end of the flexible tip member is disposed within the sleeve and between the proximal and distal ends of the sleeve, thereby positioning the flexible tip member near the light source. The device of claim 1, wherein the flexible fiber optic tip member is unitarily formed. 
gdje vršni element fleksibilnog optičkog vlakna se dijelom nalazi u tuljcu, tako da udaljeni kraj vršnog elementa fleksibilnog optičkog vlakna se pruža distalno kroz otvor u udaljeni kraj tuljca, a bliski kraj vršnog elementa fleksibilnog optičkog vlakna se nalazi u tuljcu i između bliskog i udaljenog kraja tuljca, čime je konfiguriran za smještavanje vršnog elementa fleksibilnog optičkog vlakna blizu izvora svjetla.
In a preferred embodiment of this invention, the GnRH receptor antagonists have a Ki of less than 10 uM, and more preferably less than 1 uM, and even more preferably less than 0.1 uM (i.e., 100 nM). 
U poželjnoj izvedba ovog izuma vrijednost Ki; za antagoniste receptora GnRH je manja od 10 uM, poželjnije manja od 1 uM, a još poželjnije manja od 0,1 uM (tj. 100 nM).
a second supply path branched from the first supply path for supplying the saturated steam toward the mold to heat the raw tire from outside; 
drugi opskrbni put (410; 410a-410h) razgranan od prvog opskrbnog puta za opskrbu zasićenom parom prema kalupu za zagrijavanje sirovog pneumatika izvana;
In yet a further aspect there is provided the polymorph in crystalline form. 
U još daljnjem aspektu osigurava se polimorf u kristalnom obliku.
In the example shown, scraper 8 is defined by a flat, substantially T-shaped plastic or metal plate 8, which has a central leg with a C-shaped end to engage, in freely rotating and easily releasable manner, a cylindrical pin 10 coaxial with axis B, and comprises, along the whole of the top crosspiece, a wedge-shaped ridge or appendix 8a defining the wedge-shaped transverse edge 8a of scraper 8. 
HR P20090133 T3 U prikazanom primjeru, strugač 8 je definiran ravnom, u biti T-oblikovanom plastičnom ili metalnom pločom 8, koja ima centralnu nožicu sa C-oblikovanim krajem da zahvati, na slobodno rotirajući i lako oslobađajući način, cilindrični štift 10 koaksijalan s osi B, i sadrži duž cijelog gornjeg poprečnog komada, klinasto oblikovani greben ili dodatak 8a koji definira klinasto oblikovani poprečni brid 8a strugača 8.
The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein Rb is H, methyl or ethyl. 
Tvar iz patentnog zahtjeva 3, pri čemu je Rb H, metil ili etil.
The concentration of the flavouring agent with which the popcorn kernels is to be flavoured and the phase in which the flavouring is packaged depend on the type of flavouring and the desired intensity of the flavour in the final product, popcorn. A method for the packaging of popcorn kernels for popping in microwave ovens; characterised in that the method comprises a step in which popcorn kernels, a distribution agent, and a flavouring agent are dispensed into a microwaveable package through an arrangement of independent discharge openings, adapted to supply and dose, respectively, the popcorn kernels, distribution agent, and flavouring agent, 
HR P20181674 T1 PATENTNI ZAHTJEVI Postupak pakiranja zrna za kokice, namijenjenim pripravi kokica u mikrovalnim pećima; naznačen time što se pakiranje provodi bez prisutnosti masti ili ulja, te što se postupak sastoji u koraku razdjeljivanja zrna za kokice sredstvom za raspodjeljivanje, koje je emulzija ili smjesa najmanje dva emulgirajuća ili emulgentna prehrambena dodatka, uz dodatak sredstva za aromatiziranje u pakiranje kojeg se može peći mikrovalovima kroz neovisne otvore za pražnjenje, prilagođene za dodavanje odnosno doziranje, na zrna za kokice, sredstva za raspodjeljivanje i sredstva za aromatiziranje.
A B2 agonist as defined in any one of claims 1 and 3 to 7, for simultaneous, concurrent, separate or sequential use in combination with an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 11 or 12. 
Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (b) antagonistom muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
The pharmaceutical composition of Claim 19, wherein the composition comprises a B2 adrenergic receptor agonist and a steroidal anti-inflammatory agent. 
Farmaceutski pripravak iz Patentnog zahtjeva 19, naznačen time, da taj pripravak sadrži agonist B2 adrenergičkih receptora i steroidno protuupalno sredstvo.
The target-binding moiety toxin conjugate of claim 9 or 10, wherein the antigen binding fragment is selected from the group consisting of Fab, F(ab')2, Fd, Fv, single-chain Fv, and disulfide-linked Fvs (dsFv). 
Konjugat za ciljno vezanje djela toksina prema bilo kojem od zahtjeva 1 do 11, naznačen time što je fragment koji se veže za antigen odabran iz skupine koja se sastoji od Fab, F(ab')2, Fd, Fv, jednolančanog Fv, i Fvs koji su povezani sa disulfidom (dsFv).
The third outer dimension may be the thickness of the packaging. 
Treća vanjska dimenzija može biti debljina pakiranja.
A compound of formula VIb: or a salt thereof wherein R1 is hydrogen or an amino protecting group. 
Spoj, naznačen time, da ima formulu VIb: V 15 ili njegova sol, gdje R! je vodik ili jedna amino-zaštitna skupina.
when the SAO parameters of the current block are not determined to be equal to the SAO parameters of an upper block, generate SAO type information of the current block by performing entropy encoding, and generate a bitstream including the slice header, the left SAO merging information, the upper SAO merging information, and the SAO type information of the current block, 
Postupak dekodiranja videa prema zahtjevu 1, naznačen time, da kada gornja informacija pomaka spajanja ukazuje da je parametar pomaka trenutnog bloka određen prema parametru pomaka gornjeg bloka, parametar pomaka trenutnog bloka se ne dobiva iz toka bitova.
Table 3 Inhibition of U937 monocyte adhesion to activated HMEC-1 human endothelial cells 
Tablica 3, Inhibicija U937 adhezije monocita na aktivirane HMEC-1 humanih endotelnih stanica
The device according to claim 1, wherein at least one coupling device is located between the carrier shaft (S) and the faster stationary transmission shaft (1) of the epicyclic gear (3). 
spojen između prijenosne osovine (S) i sporije osovine stacionarnog zupčanika (2) epicikličkog planetarnog prijenosnika, ili spojen između prijenosne osovine (S) i brže osovine stacionarnog zupčanika (1) epicikličkog planetarnog prijenosnika, ili
The method of claim 1, wherein the compound has Formula IX or a pharmaceutically acceptable salt, solvate, hydrate, single stereoiomer, mixture of stereoisomers or racemic mixture of stereoisomers thereof, wherein: 
Tvar 1z patentnog zahtjeva 1, pri čemu tvar ima formulu IX m" We ili njena farmaceutski prihvatljiva sol, solvat, hidrat, pojedinačni stereoizomer, smjesa stereoizomera ili racemična smjesa njenih stereoizomera, pri čemu:
The dismantling system (5) according to claim 1, wherein the retaining means (52) comprise at least one flange suitable for holding the casing (12) by means of driving said flange on the base of the casing (12). 
Sustav za rastavljanje (5) u skladu s patentnim zahtjevom 1, naznačen time što element za držanje (52) ima najmanje jednu prirubnicu, pogodan za držanje kućišta (12), pokretanjem navedene prirubnice na podnožje kućišta
A first requirement for the zirconia particles is that the second crystalline phase thereof, within the selected particle size range, is “stable” under “standard” conditions, i.e. standard pressure (101.3 kPa) and at least one temperature in the range of 10-50° C., i.e. corresponding to the conditions under which the product (typically a composite material) is used. 
Prvi zahtjev za veličinu čestica cirkonijeva oksida je da je njihova druga kristalna faza unutar odabranog raspona veličine "stabilna" pod "standardnim" uvjetima, tj. standardnom tlaku (101.3 kPa) i najmanje jednoj temperaturi u rasponu od 10-50 "C, tj. da odgovara uvjetima po kojim se produkt (tipično kompozitni materijal) koristi. 2.
According to the present invention there is provided a maleate salt of AZD2171 in a first crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with specific peaks at 2-theta=21.5, 16.4, 24.4, 20.7, 25.0, 16.9, 12.1, 22.2, 17.4 and 17.6° wherein said values may be plus or minus 0.5° 2-theta. 
Maleatna sol 4-((4-fluoro-2-metil-12-indol-S-il)oksi)-6-metoksi-7-(3-(pirolidan-1-il)propoksi)kinazolina, u kristalnoj Formi A, prema zahtjevu 1, naznačena time, da navedena sol ima uzorak difrakcije X-zraka na puderu sa specifičnim vršcima kod 2-theta - 21.5, 16.4, 24.4, 20.7, 25.0, 16.9, 12.1, 22.2, 17.41 17.6" pri čemu navedene vrijednosti mogu varirati plus ili minus 0.5 2-theta.
A method for obtaining the Letermovir according to any of the embodiments 1 to 5 comprising the following steps: 
Letermovir prema bilo kojem od zahtjeva 1 do 3, pri čemu je dobiveni Letermovir procesiran suhom granulacijom.
insertion of an exogenous nucleic acid sequence; 
(d) inserciju sekvence egzogene nukleinske kiseline;
The process of any one of claims 7-9, wherein the EGF is dissolved in an aqueous solution containing a cationic surfactant with a concentration above its critical micellar concentration. 
Posupak iz bilo kojeg od patentnih zahtjeva 7-9, pri čemu se EGF rastvara u vodenom rastvoru koji sadrži kationski surfaktant s koncentracijom iznad njegove kritične micelarne koncentracije.
The composition of claim 21, or a pharmaceutically acceptable salt form thereof, which is in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
The method according to claim 9, wherein it further comprises the step of administering in vitro the selected molecule in a centronuclear myopathy non-human animal model or a part thereof and analyzing the effect on the myopathy onset or progression. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što dodatno uključuje korak primjene in vitro birane molekule kod centronuklearne miopatije na životinji koja nije čovjek kao modelu, ili njezinom dijelu, te analizi učinka na početak ili napredovanje miopatije.
PDE4 (Phosphodiesterase 4) inhibitors, such as roflumilast and cilomilast, for the treatment of asthma, COPD, allergic dermatitis, allergic conjunctivitis, etc; or 
Spoj u skladu s patentnim zahtjevom 13, naznačen time što je alergijska bolest bronhijalna astma, alergijski rinitis, alergijski dermatitis, alergijski konjunktivitis ili alergija na hranu.
An expression vector comprising the nucleic acid molecule of claim 9. 
Vektor ekspresije koji sadrži molekulu nukleinske kiseline prema zahtjevu 9.
A device according to claim 1, wherein the lever is pivotally connected to the head by a rotational axis. 
Naprava u skladu s patentnim zahtjevom 1, naznačena time što je poluga zakretno povezana s glavom (20) preko osi vrtnje (L).
So ultrasound should typically be used for about 60 sec. 
Tako ultrazvuk treba tipično biti korišten oko 60 sekundi.
In addition, some of the compounds of structure (I) may also form solvates with water or other organic solvents. 
Uz to, neki od spojeva strukture (1) također mogu tvoriti solvate s vodom ili drugim organskim otapala.
The process of claim 1, wherein the dextrose equivalent (DE) of the activated glucose syrup is in the range of from 0.1 to 1.0, preferably is about 0.3. The process of claim 1 or 2, wherein the complex of iron (III) hydroxide and activated glucose syrup has at least three -COOH groups per glucose syrup molecule. 
Proces u skladu s patentnim zahtjevom 1, pri čemu je dekstrozni ekvivalent (DE) aktiviranog glukoznog sirupa raspona od 0,1 do 1,0, preferabilno otprilike 0,3 i/ili dobiveni kompleksni spoj željezo (III) hidroksida i aktiviranog glukoznog sirupa ima najmanje tri –COOH grupe po molekuli glukoze, što ukazuje da je glukozni sirup aktiviran.
If organs of fungi are used, then according to the invention they may preferably be spores, conidia, blastospores, chlamydospores, sclerotia or hyphae segments or a mixture of said organs. 
Postupak prema zahtjevu 6, naznačen time da se spore, konidiji, klamidospore ili sklerociji izoliraju nakon obrade prosijavanjem, filtracijom, sortiranjem pomoću zraka ili postupcima centrifugiranja.
In this test the oral efficacy of a compound of the invention for the prevention of castration-induced trabecular bone mineral density (BMD) loss in male rats was evaluated. 
U ovom ispitivanju procijenjena je oralna djelotvornost spoja prema ovom izumu u sprječavanju smanjenja mineralne gustoće trabekularne kosti (BMD) uzrokovanog kastracijom kod mužjaka štakora.
An intermediary position is shown in Figure 2b where the container 2 and the base unit 3 have moved a distance downwards. 
Međufazni položaj prikazan je na slici 2b, gdje su se spremnik 2 i osnovna jedinica 3 malo pomaknuli prema dolje.
In the meantime, the required amount of stearyl alcohol is melted at a temperature of approximately 70 °C. 
5. U međuvremenu, potrebna količina stearil alkohola je otopljena pri temperaturi od približno 70.
The antibody drug conjugate of claim 1, wherein the anti-DLL3 antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, CDR-grafted antibody, humanized antibody, human antibody, primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, anti-idiotypic antibody, diabody, Fab fragment, F(ab′)2 fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je protutijelo anti-DLL3 odabrano iz skupine koju čine monoklonalno protutijelo, kimerno protutijelo, CDR-cijepljeno protutijelo, humanizirano protutijelo, ljudsko protutijelo, primatizirano protutijelo, multispecifično protutijelo, bispecifično protutijelo, monovalentno protutijelo, multivalentno protutijelo, diabody, Fab-fragment, F(ab'),-fragment, Fv- fragment i ScFv-fragment; ili njegov imunoreaktivni fragment koji se specifično veže na epitop unutar DSL-domene od DLI.3-proteina prema SEQ ID NO:3 ili SEQ ID NO:4.
A recombinant AAV vector comprising a transgene encoding acid beta glucosidase for use in a method of treating Gaucher disease in a subject, wherein the method comprises administering the recombinant AAV vector to at least one ventricle of the brain, whereby said transgene is expressed in a therapeutically effective amount. 
Rekombinantni AAV vektor koji sadrži transgen kodira kiselinu sfingomijelinazu za upotrebu u postupku liječenja Niemann–Pickove bolesti tip A ili Niemann–Pickove bolesti tip B kod subjekta, naznačen time da navedeni rekombinantni AAV vektor je AAV5 vektor i pri čemu postupak sadrži davanje vektora u barem jednu ventrikulu mozga od subjekta, pri čemu se navedeni transgen eksprimira i eksprimirani proizvod proteina se dovodi u središnji živčani sustav, te proizvoljno, u visceralne organe.
The immunogenic composition for use according to claim 1 or 2, wherein the adjuvant further comprises a sterol, and wherein the ratio of saponin: sterol is 1:1 to 1:100 w/w. 
Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni adjuvantirani pripravak dodatno sadrži sterol, gdje se omjer saponin:sterol kreće od 1:1 do 1:100 tež./tež..
The apparatus according to claim 9, wherein the nozzles are arranged such that when the gas cooling liquid is sprayed out through the nozzles, the gas cooling liquid is sprayed into a foam which during use of the apparatus is generated by the organic material whereby it ascends from the gas generating zone into the gas collecting zone in which it continues towards the one or more biogas outlets, the one or more nozzles being adapted to spray an amount of the gas cooling liquid sufficient to prevent the foam from entering the biogas outlet. 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da su sapnice koje raspršuju tekućinu za hlađenje plina postavljene tako da tekućinu za hlađenje plina raspršuju na pjenu koju stvara organski materijal tokom rada uređaja, i koja se penje iz zone proizvodnje plina u zonu sakupljanja plina, gdje nastavlja prema jednom ili više izlaza za plin, a jedna ili više sapnica su podešene tako da raspršuju dovoljnu količinu tekućine za hlađenje plina, koja će spriječiti ulazak pjene u izlaz za bioplin.
Thus, the peptide or polypeptide of the present invention comprises 7 to 30, preferably 7 to 20, more preferably 7 to 16, most preferably 8, amino acid residues. According to the invention, however, also longer peptides may very well be employed as anti-alpha-synuclein-antibody-inducing antigens. 
Sastav za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da peptid ili polipeptid sadrži od 7 do 30, poželjno od 7 do 20, još bolje od 7 do 16, te najbolje 6 aminokiselinskih ostataka.
The neurodegenerative disease may be associated with cognitive impairment. In particular, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy (PSP), multiple system atrophy (MSA), Lewy body dementia, Parkinson's disease dementia, epilepsy, stroke, Huntington's Chorea, cerebral hypoxia, multiple sclerosis, and peripheral neuropathy. 
Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da neurodegenerativna bolest je odabrana iz skupine koju čine Alzheimerova bolest, Parkinsonova bolest, progresivna supranuklearna paraliza (PSP), multipla sistemska atrofija (MSA), demencija s Lewyjevim tjelešcima, Parkinsonova bolest s demencijom, epilepsija, kap, Huntingtonova korea, cerebralna hipoksija, multipla skleroza, te periferna neuropatija.
The precursor material of claim 9, wherein a sodium level within the precursor material is less than 300 ppm. 
Postupak prema zahtjevu 30, u kome je razina natrija unutar prokursor materijala manja od 300 ppm.
The composition of any preceding embodiment, wherein the composition is for oral administration. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je sastav za oralnu primjenu.
Again, it is preferred the eye disease is diabetic retinopathy in the third, fourth or fifth aspects of the invention. 
Spoj za uporabu prema zahtjevu 5 ili 7, naznačen time što je bolest oka dijabetska retinopatija.
The method as claimed in claim 1, wherein the polyolefins comprise a mixture of polyethylene and polypropylene. The method as claimed in claim 1, wherein the polyolefins are melted in at least one extruder at temperatures of up to 300° C. 
Postupak prema zahtjevu 1 ili 2, naznačen time da se poliolefini tale u barem jednom ekstruderu (E), a naročito u dvopužnom ekstruderu, na temperaturama do 300°C, a naročito na temperaturama između 200°C i 300°C.
Polyoxyethylene alkyl ethers such as those commercially available under the trademark BRIJ, e.g., Brij 92V and Brij 35. 
8) Polioksietilen alkil etere poput onih komercijalno raspoloživih pod zaštićenim nazivom BRIJ, na primjer Brij 92V 1 Brij 35.
Further, it is especially preferred to use 2-acetylthioisosorbide-5-mononitrate (compound (12)), a tautomer, a pharmaceutically acceptable salt and/or a solvate thereof: as active ingredient for the manufacture of a pharmaceutical composition for the prevention and/or treatment of thrombosis, ischemia, cell/tissue damage induced by ischemia and/or by ischemia and reperfusion, hypertension, vasospasm, atherosclerosis and/or cardiac graft vasculopathy. 
HaC S Kr kao aktivnog sastojka za proizvodnju farmaceutskog sastava za prevenciju i/ili liječenje tromboze, ishemije, ozljede stanica/tkiva uzrokovane ishemijom i/ili ishemijom i reperfuzijom, hipertenzije, vazospazme, ateroskleroze i/ili kardijalne vaskulopatije grafta.
(b′) converting the hydroxyl group of the compound of formula 5 or a salt thereof, into a leaving group, L, to provide a compound of formula 1 or a salt thereof. 
(b") pretvaranje hidroksil skupine spoja prema formuli 5 ili njegove soli, u izlaznu skupinu, L, čime se dobiva spoj formule 1 ili njegova sol.
The residue was suspended in water and extracted with ethyl acetate. 
Ostatak se suspendira u vodi i ekstrahira etil acetatom.
Before arriving at the preferred concentration range of SDS, IL-2 was prepared by the method described above, except that large samples (~300mg IL-2) were removed at various points during the diafiltration for turbidity investigation, in order to establish the effect of SDS on IL-2 aggregation. 
Prije postizanja pogodnog opsega koncentracije od SDS, IL-2 je pripravljen metodom koja je gore opisana, osim što su veliki uzorci (-300mg IL-2) odstranjeni na različitim točkama za vrijeme diafiltracije radi istraživanja zamućenosti da bi se utvrdio učinak SDS na IL-2 agregiranje.